Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.14), $0.21 better than the analyst estimate of ($1.35). Revenue for the quarter came in at $99 million versus the consensus estimate of $98.34 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.